13 Liver Cancer Clinical Trials in Chicago, IL (2026)

Q: How do I join a clinical trial in Chicago?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you.

Recruiting Liver Cancer Studies in Chicago

NCT06084234Recruiting

National Liver Cancer Screening Trial

The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or pati...

Chicago, ILPHASE45,500 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT06921785Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremel...

Chicago, ILPHASE31,220 participantsAstraZeneca

View Study Details

NCT06109272Recruiting

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic...

Chicago, ILPHASE2660 participantsAbbVie

View Study Details

NCT06914648Recruiting

The Dragon PLC Trial (DRAGON-PLC)

The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients w...

Chicago, ILNA358 participantsMaastricht University

View Study Details

NCT07717437Recruiting

DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE. This ...

Chicago, IL350 participantsMaastricht University Medical Center

View Study Details

NCT06084481Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is gi...

Chicago, ILPHASE1325 participantsAbbVie

View Study Details

NCT05620771Recruiting

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment...

Chicago, ILPHASE2200 participantsNorthwestern University

View Study Details

NCT07291076Recruiting

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcin...

Chicago, ILPHASE1198 participantsBristol-Myers Squibb

View Study Details

NCT05797805Recruiting

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least on...

Chicago, ILPHASE1178 participantsIterion Therapeutics

View Study Details

NCT06600321Recruiting

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended d...

Chicago, ILPHASE1158 participantsAlnylam Pharmaceuticals

View Study Details

NCT05168163Recruiting

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer...

Chicago, ILPHASE2122 participantsAcademic and Community Cancer Research United

View Study Details

NCT07042919Recruiting

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

This phase Ib/II trial tests the safety, side effects, and best dose of zanzalintinib and how well it works in treating patients with hepatocellular (liver) cancer that may have spread from where it f...

Chicago, ILPHASE159 participantsDevalingam Mahalingam

View Study Details

NCT06501625Recruiting

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

The objective of this study is to investigate the safety, tolerability and preliminary activity of ivosidenib in combination with durvalumab and gemcitabine/cisplatin as first-line therapy in particip...

Chicago, ILPHASE152 participantsInstitut de Recherches Internationales Servier

View Study Details

About Liver Cancer Clinical Trials in Chicago

Liver cancer most commonly presents as hepatocellular carcinoma (HCC) and is often associated with chronic liver disease or hepatitis. It is one of the fastest-growing causes of cancer death. Treatment options include surgery, liver transplant, ablation, and systemic therapies.

There are currently 13 liver cancer clinical trials recruiting participants in Chicago, IL. These studies are seeking a combined 9,380 participants. Research is being sponsored by University of Texas Southwestern Medical Center, AstraZeneca, AbbVie and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Liver Cancer Clinical Trials in Chicago — FAQ

Are there liver cancer clinical trials in Chicago?

Yes, there are 13 liver cancer clinical trials currently recruiting in Chicago, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What liver cancer treatments are being tested?

The 13 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for liver cancer.

Data updated August 31, 2026 from ClinicalTrials.gov